Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. 
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $CANSINOBIO (06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $RECBIO-B (02179.HK)$ , $INNOCARE (09969.HK)$ and ...